Author: Ian Mason

A raft of data on licensed and investigational multiple sclerosis treatments will be unveiled by Novartis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, which opens today (October 10) in Lyon, France.

A raft of new results plus an update on ongoing clinical trials featuring Eisai’s epilepsy portfolio have been presented at the European Congress on Epileptology held this week in London.

Eisai’s ambitious plans for leadership of the European epilepsy market were unveiled this week at the opening of a new production facility at the company’s £100 million EMEA research and commercial headquarters in Hatfield, UK.

The UK’s Medicines and Healthcare products Regulatory Agency’s latest ‘drug safety update’ (February) flags the increased cardiovascular monitoring required when patients are given their first dose of Novartis’ oral multiple sclerosis drug Gilenya.

Hormone replacement therapies should carry a stronger warning about the risk of causing potentially fatal asthma exacerbations in susceptible women, says the author of a major study presented at the European Respiratory Society congress in Amsterdam.